Mineralys Therapeutics Inc. Chief Commercial Officer Eric Warren sold 7,437 common shares on Aug. 21 for a total of $193,188 under a prearranged trading plan adopted on March 27.
The shares were sold at a weighted average price of $25.9767, with transaction prices ranging from $25.82 to $26.15. Warren had acquired the shares through option exercises at $13.24 each, totaling $98,465 in upfront costs before the sale.
Following the transaction, Warren holds 38,400 direct common shares and retains 238,001 unexercised options. The company's market capitalization stands at approximately $2.23 billion, with shares up 78.7% over the past year.
Mineralys reported a second-quarter 2026 adjusted loss of $2.85 per share, missing analyst expectations of a $2.63 per share loss. The company develops lorundrostat, a blood pressure medication currently in clinical development.
The options sold were granted with progressive vesting terms: 25% vested on the first anniversary of the grant date, with the remainder vesting in 36 equal monthly installments thereafter.
